Home About Us Pipeline News Investors Contacts Careers


Puma Biotechnology, Inc. Corporate Fact Sheet


NEWS

EVENTS

CONTACT


Dec. 12, 2014 - Puma Biotechnology Announces Positive Interim PB272 (Neratinib) Phase II Data at 2014 CTRC-AACR San Antonio Breast Cancer Symposium
Interim Phase II Results Demonstrate Efficacy of PB272 in Combination with Temsirolimus in HER2+ Metastatic Breast Cancer
Read

Dec. 2, 2014 - Puma Biotechnology Updates Timeline for Filing New Drug Application
Read

Nov. 13, 2014 - Puma Biotechnology Announces Positive Top Line Results from PB272 Phase II Trial in HER2 Positive Metastatic Breast Cancer (NEfERTT Trial)
Read

Nov. 12, 2014 - Puma Biotechnology to Present at Stifel 2014 Healthcare Conference
Read


  • 33rd Annual J.P. Morgan Healthcare Conference

    More

Puma Biotechnology, Inc.
10880 Wilshire Blvd., Suite 2150
Los Angeles, CA 90024
424-248-6500 Main
424-248-6501 Fax
info@pumabiotechnology.com


Puma Biotechnology 2013 Annual Report